 Home > Active Ingredient News > Antitumor Therapy > Bayer had a net loss of approximately 10.5 billion euros last year, and the top sales of rivaroxaban faced a patent cliff

Bayer had a net loss of approximately 10.5 billion euros last year, and the top sales of rivaroxaban faced a patent cliff

 Last Update: 2021-03-19
 Source: Internet
 Author: User

Tags

10 3 ground

benefits gene therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On the 25th local time, Bayer announced its 2020 fiscal year, with total annual revenue of 41.

Among its four main businesses, Bayer's pharmaceutical business achieved revenue of 17.

In 2020, Bayer’s best-selling drug is the anticoagulant Xarelto (rivaroxaban).

Xarelto is the most widely used non-vitamin K antagonist oral anticoagulant (NOAC) in the world, developed by Bayer and Johnson & Johnson.

However, the top-selling rivaroxaban patent has expired in China in 2020, and it will also expire in EU countries in 2023, the United States in 2024, and Japan in 2025.

Also facing the patent cliff is not only the top spot, but also the second-ranked ophthalmic drug Eylea (Aflibercept), which was jointly developed by Bayer and Regeneron.

To this end, Bayer also announced in September last year that it will accelerate the pace of transformation.

From a strategic perspective, Bayer focuses on specific areas of cell and gene therapy, including stem cell therapy for different indications (focusing on induced pluripotent stem cells or iPSCs), gene enhancement, gene editing, and allogeneic cells therapy.

Stem cells leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.